WOCKHARDT LIMITED

Wockhardt Towers, Bandra-Kurla Complex Bandra (East), Mumbai 400 051, India



UNAUDITED CONSOLIDATED FINANCIAL RESULTS

FOR THE QUARTER ENDED 30TH SEPTEMBER, 2011

(Rs. in Million)

PARTICULARS	QUARTER	% TO	QUARTER	% TO	GROWTH	SIX MONTHS	% TO	SIX MONTHS	% TO	GROWTH	YEAR	n Million) % TO
PARTICULARS	ENDED	SALES	ENDED	% 10	GROWIN %	ENDED	% 10 SALES	ENDED	% 10 SALES	GROWIN %	ENDED	SALES
	30/09/2011	OALLO	30/09/2010	OALLO	70	30/09/2011	OALLO	30/09/2010	OALLO	70	31/03/2011	OALLO
Income from Operations	11,105	100.0	9,401	100.0		21,637	100.0	18,617	100.0		37,512	
Total Expenditure	7,872	70.9	7,203	76.6	9.3	15,295	70.7	14,616	78.5	4.6	28,425	75.8
a) (Increase)/Decrease in stock	(717)	(6.5)	370	3.9	(293.8)	(844)	(3.9)		2.2	(307.9)	617	1.6
b) Consumption of raw material	3,390	30.5	2,342	24.9	44.7	5,734	26.5	4,753	25.5	20.6	8,750	23.3
c) Purchase of Finished Goods	<u>1,660</u>	14.9	<u>1,191</u>	12.7	39.4	<u>3,194</u>	14.8	<u> 2821</u>	15.2	13.2	<u>5,786</u>	15.4
Material Consumption	4,333	39.0	3,903	41.5	11.0	8,084	37.4	7,980	42.9	1.3	15,153	40.4
d) Staff Cost	1,149	10.3	1,267	13.5	(9.3)	2,459	11.4	2,580	13.9	(4.7)	5,247	14.0
e) R & D expenditure	157	1.4	122	1.3	28.7	345	1.6	279	1.5	23.7	483	1.3
f) Other expenditure	2,233	20.1	<u>1,911</u>	20.3	16.8	<u>4,407</u>	20.4	3,777	20.3	16.7	7,542	20.1
Other Expenditure	3,539	31.9	3,300	35.1	7.2	7,211	33.3	6,636	35.6	8.7	13,272	35.4
Gross Profit before Interest,	3,233	29.1	2,198	23.4	47.1	6,342	29.3	4,001	21.5	58.5	9,087	24.2
Depreciation & Taxation												
Interest/ Financing Cost												
(a) Interest	398	3.6	565	6.0	(29.6)	983	4.5	1,209	6.5	(18.7)	2,671	7.1
(b) (Income)/Expense due to Exchange Rate	430		211			467					(4.266)	
Fluctuation	430		211			407		O			(1,366)	
Depreciation	280	2.5	299	3.2	(6.4)	660	3.1	594	3.2	11.1	1,166	3.1
Other Income	28	-	35	-	-	82	-	71	-	-	159	
Profit/(Loss) Before Tax before exceptional items	2,153	19.4	1,158			4,314	19.9	2,263			6,775	18.1
Exceptional Item Profit/(Loss)	(681)		(2,020)			(681)		(4,176)			(5,732)	
Profit/(Loss) before Tax	1,472	13.3	(862)	(9.2)	270.8	3,633	16.8	(1,913)	(10.3)	289.9	1,043	2.8
Provision for Taxation	219		73			481		102			338	
Deferred Taxation	25		40			(21)		100			(252)	
Profit/(Loss) After Tax	1,228	11.1	(975)	(10.4)	225.9	3,173	14.7	(2,115)	(11.4)	250.0	957	2.6
Add: Share of Profit/(Loss) from Associates	47		8			42		(16)			(52)	
Net Profit/(Loss)	1,275	11.5	(967)	(10.3)	231.9	3,215	14.9	(2,131)	(11.4)	250.9	905	2.4
			- 4-	,				·	,			
Paid-up Equity Share Capital (Rs 5/-each)	547		547		-	547		547		-	547	
Reserves excluding Revaluation Reserve (as											4.054	
per last audited Balance-Sheet)	-		-		-	-		-		-	1,251	
Earning Per Share			,									
Basic Earning Per Share (Rs)	11.66		(8.84)			29.38		(19.47)			8.27	
Diluted Earning Per Share (Rs)	11.66		(8.84)			29.38		(19.47)			8.27	

Public Shareholding					
- Number of Shares	28,421,193	28,275,055	28,421,193	28,275,055	28,392,021
- Percentage to Paid-up Capital	25.97%	25.84%	25.97%	25.84%	25.94%
Promoters and promoter group shareholding					
a) Pledged/ Encumbered					
- Number of shares	70,158,917	67,708,917	70,158,917	67,708,917	70,158,917
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	87.06%	84.02%	87.06%	84.02%	87.06%
-Percentage of shares (as a % of the total share capital of the Company)	64.11%	61.87%	64.11%	61.87%	64.11%
b) Non-encumbered					
- Number of shares	10,426,465	12,876,465	10,426,465	12,876,465	10,426,465
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	12.94%	15.98%	12.94%	15.98%	12.94%
-Percentage of shares (as a % of the total share capital of the Company)	9.53%	11.77%	9.53%	11.77%	9.53%

Notes To Consolidated Financials:-

1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 12, 2011.

2) Statement of Assets and Liabilities

(Rs. in Million)

		(IXS. III WIIIIOII)			
Particulars	As at 30/9/2011		As at 30/9/2010		
	(Unaudite	d)	(Unaudited)		
SHAREHOLDERS' FUNDS:					
(a) Capital	8,054		7,618		
(b) Reserves & Surplus	6,480	14,534	1,120	8,738	
LOAN FUNDS		37,937		40,163	
TOTAL		52,471		48,901	
FIXED ASSETS		36,217		32,693	
INVESTMENTS		938		932	
DEFERRED TAX ASSET (NET)		823		371	
CURRENT ASSETS, LOANS AND ADVANCES					
(a) Inventories	8,117		7,316		
(b) Sundry Debtors	7,523		6,153		
(c) Cash and bank Balances	5,339		3,690		
(d) Loans and Advances	2,499		3,551		
	23,478		20,710		
Less : Current Liabilities and Provisions					
(a) Liabilities	9,191		9,527		
(b) Provisions	1,144		384		
	10,335	13,143	9,911	10,799	
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)		0		0	
PROFIT AND LOSS ACCOUNT		0		2,187	
FOREIGN CURRENCY TRANSLATION RESERVE		1,350		1,919	
TOTAL		52,471		48,901	

- 3) Exceptional items for the quarter ended September 30, 2011 mainly comprises of settlement of loan/disputed derivative liabilities Rs. 777 million and reversal of excess provision for the restructuring cost in France Rs. 174 million.
- 4) During the quarter, Company has issued 10,921,071 Non Convertible Cumulative Redeemable Preference Shares (NCRPS) of Rs. 5/- each amounting to Rs. 54.61 million to various banks/financial institutions. The NCRPS are redeemable in the year 2018.
- 5) Against the pending petition, the Company has filed a consent decree in the Hon'ble High Court of Bombay and has agreed withdrawal by FCCB holders of Rs. 1,150 million deposited earlier and further agreed to pay balance FCCB outstanding along with interest on reducing balance, by August 2012. Further, the Hon'ble High Court of Bombay has permitted the divestment of Nutrition Business.
- 6) The Company has entered into definitive agreement on August 2, 2011 with Danone, for divestment of the Nutrition business. As the said transaction is subject to various closing conditions and approvals, the impact of this transaction will be accounted during the quarter in which the same is closed.
- As on Julyl 1, 2011 the Company had no investors complaints pending. During the quarter, the Company has not received any complaints. Accordingly, no complaints are pending as on September 30, 2011.
- 8) The Company is exclusively into Pharmaceutical business Segment.
- Previous period figures have been recast/ re-classified to conform to the current period's presentation.